Hualan Biological Engineering (SZSE:002007) Risk Assessment

View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Hualan Biological Engineering is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Hualan Biological Engineering's Risk Assessment

For the Biotechnology subindustry, Hualan Biological Engineering's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hualan Biological Engineering's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's Risk Assessment falls into.

Hualan Biological Engineering (SZSE:002007) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Hualan Biological Engineering Risk Assessment Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Hualan Biological Engineering (SZSE:002007) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003

Website

http://www.hualanbio.com

Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.

Executives

An Kang	Directors, executives
Pan Ruo Wen	Executives
An Wen Qi	Executives
Wang Qi Ping	Directors, executives
Fan Bei	Directors, executives
Ma Xiao Wei	Executives
Xie Jun Min	Directors, executives
Zhang Bao Xian	Executives
Lv Cheng Yu	Securities Affairs Representative
Zhang Jin Gang	Independent director
Wang Li Ting	Independent director
Ma Li	Supervisors
Sun Zhen Guo	Supervisors
Chen Lei Shan	Supervisors
Yang Bao Ping	Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines